Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Pituitary stalk interruption syndrome (PSIS) is a congenital abnormality of the pituitary that is responsible for pituitary deficiency and is usually characterized by the triad of a very thin or interrupted pituitary stalk, an ectopic (or absent) posterior pituitary (EPP) and hypoplasia or aplasia of the anterior pituitary visible on MRI. In some patients the abnormality may be limited to EPP (also called ectopic neurohypophysis) or to an interrupted pituitary stalk.
Features include always present findings: Ectopic posterior pituitary; and very common findings: Abnormality of the hypothalamus-pituitary axis, Failure to thrive, and Short stature. 16 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Hormones | 7 | Ectopic posterior pituitary, Abnormality of the hypothalamus-pituitary axis, Hypothyroidism |
Biomarker and diagnostic research for pituitary stalk interruption syndrome has been reported in the published literature.
Phenotype severity distribution: 1 always present feature, 3 very common features, 4 common features.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered, 1 recruiting. Interventions under study include drug therapy. Pipeline includes 1 PHASE3. Research is primarily industry-sponsored.
44 publications have been identified in PubMed for pituitary stalk interruption syndrome. Research spans Case Report / Case Series (57%), Epidemiology / Natural History (20%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 25 | 57% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 11:12 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Brain and nerves |
3 |
Intellectual disability, Seizure, Global developmental delay |
Growth and development | 2 | Failure to thrive, Short stature |
Eyes | 1 | Septo-optic dysplasia |
Disease patterns and progression |
9 |
20% |
Research summaries | 7 | 16% |
Testing and diagnosis research | 2 | 5% |
Laboratory research | 1 | 2% |
Yu LH (2026). [PMID: 41942328](https://pubmed.ncbi.nlm.nih.gov/41942328/). *Zhonghua nei ke za zhi*. [Case Report / Case Series]
Meller LLT (2026). [PMID: 41499205](https://pubmed.ncbi.nlm.nih.gov/41499205/). *Endocrinology, diabetes & metabolism case reports*. [Case Report / Case Series]
Hashem S (2026). [PMID: 42088401](https://pubmed.ncbi.nlm.nih.gov/42088401/). *Radiol Case Rep*. [Case Report / Case Series]
Fu L (2026). [PMID: 41935302](https://pubmed.ncbi.nlm.nih.gov/41935302/). *BMC endocrine disorders*. [Epidemiology / Natural History]
Chrzanowska J (2026). [PMID: 41844520](https://pubmed.ncbi.nlm.nih.gov/41844520/). *Clinical endocrinology*. [Review / Meta-Analysis]
Aouchiche K (2026). [PMID: 42054264](https://pubmed.ncbi.nlm.nih.gov/42054264/). *Horm Res Paediatr*. [Epidemiology / Natural History]
Alaqili AK (2025). [PMID: 39809477](https://pubmed.ncbi.nlm.nih.gov/39809477/). *BMJ case reports*. [Case Report / Case Series]
Félix Cabral M (2025). [PMID: 41091595](https://pubmed.ncbi.nlm.nih.gov/41091595/). *Acta medica portuguesa*. [Case Report / Case Series]
Choure A (2025). [PMID: 39896953](https://pubmed.ncbi.nlm.nih.gov/39896953/). *AACE clinical case reports*. [Case Report / Case Series]
Jiang D (2025). [PMID: 40044792](https://pubmed.ncbi.nlm.nih.gov/40044792/). *Scientific reports*. [Epidemiology / Natural History]